Transfection Innovations and the Impact on Cell & Gene Therapy
Uncover cutting-edge transfection innovations driving higher AAV titers and percent-full capsids. Learn how Mirus Bio partners with labs to streamline AAV production.
Unlock the science behind groundbreaking transfection innovations designed to elevate your AAV workflow. See how our R&D expertise translates into better results for your cell and gene therapy research.
Your success us built on innovation. Learn how to accelerate your AAV pipeline; improve your titers, percent-full capsids, and reduce your costs using our expertise.
Behind every great discovery is a great solution. Find out how our research fuels your cell and gene therapy success with better tools and insights.
Elevate your titers and percent-full capsids with transfection solutions designed for impact. Our R&D team works behind the scenes so you can lead the way in cell and gene therapy.
Explore the transformative impact of next-gen transfection platforms
Discover how top therapeutics organizations are preparing for the future wave of drug assets, shown through key field growth metrics and absolute full titer demand.
CDMOs target 95% full capsid and continue to optimize. Better targeting, less toxicity, and higher potency contribute to a lower cost per dose.
Highest titers and percent-full translate into fold increases in doses per batch and cost per dose.
Reduce pDNA usage by 50% and cut your cost per dose, saving your lab millions.
